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immunity showed very different profiles following RT 
compared to controls. Surprisingly, we observed very little 
variations between the different RT schedules. We performed 
FACS analyses on blood and on tumors collected 4 or 11 days 
following the 2 RT schedules or from non-irradiated mice. In 
the blood, we observed a net increase of DX5+ NK cells and an 
important decrease of eosinophil in the irradiated group of 
mice compared to the non-irradiated mice. Four days after 
RT treatment, we observed a transient decrease in neutrophil 
and Ly6Clow monocyte and a transient increase in Ly6Chigh 
monocyte that return to the level of the non-irradiated group 
at day 11. Inside the tumor, results showed a drastic 
decrease in dendritic cells following RT, no significant 
difference in F4/80+ macrophage proportion between groups, 
but RT appeared to induce a switch in macrophage 
polarization with a decrease in MHCIIhigh macrophage (M1) 
proportion and an increased MHCIIlow macrophage (M2) 
proportion.  
Conclusions: These data demonstrate that RT profoundly 
modifies several components of the tumor microenvironment, 
with minor variations according to the RT schedules. These 
modifications could impact the behavior of the primary 
tumor and should be taken into account to avoid tumor 
dissemination or for improving treatments efficacy.  
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Purpose/Objective: Cetuximab is an inhibitor of the 
epidermal growth factor receptor (EGFR) impairing the 
molecular signals for cell division. Cetuximab has been 
approved for treatment of advanced head and neck tumour 
squamous cell carcinomas (HNSCC) that are often associated 
with poor prognosis, resistance to treatments and low 5-year 
survival rate. The purpose of this study was to investigate 
correlations between responsiveness to cetuximab 
treatments and tumour oxygenation in two mouse HNSCC 
models. 
Materials and Methods: Two HNSCC cell lines (UT-SCC-2 and 
UT-SCC-14) were cultured and injected subcutaneously in 
BALB/c (nu/nu) nude mice at two sites in each mice (N = 60). 
UT-SCC-14 is sensitive in vitro for cetuximab, while UT-SCC-2 
is more resistant in vitro. After one week of tumour growth, 
half of the mice received three cycles of 50mg/kg cetuximab 
intra-peritoneally (during 9 days) and the others were kept as 
controls. All the mice were subsequently imaged with 18F-
fluoromisonidazole (FMISO) in a Siemens Focus 120 microPET. 
Volumes of interest in the tumour and background (arm 
muscle) were manually delineated and the tumour-to-
background ratio (T/B) calculated as the mean standard 
uptake value (SUV) in the considered volumes. Tumours with 
T/B≤1.5 (visibility threshold) were not discernible from the 
uptake in the surrounding area. 
Results: The results showed a positive correlation between 
FMISO uptake and tumour size in untreated tumours, with UT-
SCC-14 having higher T/B ratios than UT-SCC-2 tumours. In 
the case of treated tumours, UT-SCC-2 showed FMISO tracer 
uptake almost at the visibility threshold level, in spite of the 
similar tumour volumes with UT-SCC-14 that had significantly 
higher uptake, albeit under the values in untreated tumours. 
The oxygenation assessed based on PET FMISO of the tumour 
derived from the cell line in vitro resistant to cetuximab, UT-
SCC-2, was better than the oxygenation of the tumour based 
on the sensitive cell line UT-SCC-14 after the treatment with 
cetuximab. 
Conclusions: These results indicating a possible mechanism 
for cetuximab to influence the oxygenation of tumours may 
be exploited for maximising the therapeutic gain provided 
that further investigations are conducted. 
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Purpose/Objective: Our group has constructed an on-board 
bioluminescence tomography (BLT)/cone-beam CT (CBCT) 
guided small animal radiation research platform (SARRP) for 
preclinical radiation studies. We hypothesize that BLT 
guidance on-board the SARRP system would provide more 
accurate radiation guidance than an off-line system by 
eliminating the need of animal transportation between the 
optical system and SARRP. However, the on-board BLT system 
complicates system design, and the necessary workflow 
sequence of BLT, CBCT and irradiation is likely to result in 
low experimental throughput as compared to an off-line 
